birth defects from semaglutide GLP-1 exposure in pregnancy does not clearly raise major defect risk semaglutide birth defects Semaglutide ameliorates

We have selected four female patients with fat puffiness in the jowl, lateral to the nasolabial fold and submental (double chin) areas to undergo a treatment with injection with active principles

Preprint at bioRxiv (2024)

Semaglutide is an FDA-approved GLP-1 receptor agonist originally developed to treat Type 2 diabetes

In addition, tanshinone IIA (Tan IIA) is a diterpene extracted from the root and rhizome of Salvia miltiorrhiza Bunge

The platform offers medium-level support , with some ongoing communication and check-in capability that exceeds the bare-minimum providers but does not reach the level of comprehensive programs